Fuss Brands Corp.
FBDS evidence brief
What we can confirm
- BioSniper Score:
- 7.3 / 10
- Market Cap:
- $2.2M
- Lead Asset:
- ginseng (Approved)
What it means
What to watch
Prepared research question
What matters most for FBDS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$2.2M
Cash Runway
—
Lead Asset
ginseng (Approved)
Next Catalyst
—
Tracking 2 pipeline candidates for Fuss Brands Corp..
Run Fuss Brands Corp. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Fuss Brands Corp. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of May 21, 2026- % of float
- 0.1%
- Days to cover
- —
- Shares short
- 786
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
FBDS short interestFrequently asked questions
What is Fuss Brands Corp.'s lead drug candidate?
Fuss Brands Corp.'s most advanced tracked candidate is ginseng (Approved) for Nourish blood and kidneys, restore energy, increase endurance.
Who is the CEO of Fuss Brands Corp.?
Mr. Cheskel Meisels is the chief executive officer of Fuss Brands Corp. (FBDS).
Where is Fuss Brands Corp. headquartered?
Fuss Brands Corp. (FBDS) is headquartered in New York, NY, United States.
What therapeutic areas does Fuss Brands Corp. focus on?
Fuss Brands Corp. develops therapies across Neurology, Cardiovascular, Infectious Disease, Respiratory, Pain, Nephrology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.